Literature DB >> 30212412

Morbidity and Mortality of Crystalloids Compared to Colloids in Critically Ill Surgical Patients: A Subgroup Analysis of a Randomized Trial.

Nicholas Heming1, Laure Lamothe, Samir Jaber, Jean Louis Trouillet, Claude Martin, Sylvie Chevret, Djillali Annane.   

Abstract

WHAT WE ALREADY KNOW ABOUT THIS TOPIC: WHAT THIS ARTICLE TELLS US THAT IS NEW:
BACKGROUND: : The multicenter randomized Colloids versus Crystalloids for the Resuscitation of the Critically Ill (CRISTAL) trial was designed to test whether colloids altered mortality compared to crystalloids in the resuscitation of intensive care unit patients with hypovolemic shock. This preplanned analysis tested the same hypothesis in the subgroup of surgical patients.
METHODS: The CRISTAL trial prospectively defined patients as critically ill surgical patients whenever they underwent emergency or scheduled surgery immediately before or within 24 h of intensive care unit admission and had hypovolemic shock. The primary outcome measure was death by day 28. Secondary outcome measures included death by day 90, the need for renal replacement therapy, or the need for fresh frozen plasma transfusion.
RESULTS: There were 741 critically ill surgical patients, 356 and 385 in the crystalloid and colloid arm, respectively. Median (interquartile range) age was 66 (52 to 76) yr, and 484 (65.3%) patients were male. Surgery was unscheduled in 543 (73.3%) cases. Mortality by day 28 did not significantly differ for crystalloids 84 (23.6%) versus colloids 100 (26%; adjusted odds ratio, 0.86; 95% CI, 0.61 to 1.21; P = 0.768). Death by day 90 (111 [31.2%] vs. 122 [31.7%]; adjusted odds ratio, 0.97; 95% CI, 0.70 to 1.33; P = 0.919) did not significantly differ between groups. Renal replacement therapy was required for 42 (11.8%) patients in the crystalloids arm versus 49 (12.7%) in the colloids arm (P = 0.871).
CONCLUSIONS: The authors found no survival benefit when comparing crystalloids to colloids in critically ill surgical patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30212412     DOI: 10.1097/ALN.0000000000002413

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  2 in total

1.  Effect of Hydroxyethyl Starch vs Saline for Volume Replacement Therapy on Death or Postoperative Complications Among High-Risk Patients Undergoing Major Abdominal Surgery: The FLASH Randomized Clinical Trial.

Authors:  Emmanuel Futier; Matthias Garot; Thomas Godet; Matthieu Biais; Daniel Verzilli; Alexandre Ouattara; Olivier Huet; Thomas Lescot; Gilles Lebuffe; Antoine Dewitte; Anna Cadic; Aymeric Restoux; Karim Asehnoune; Catherine Paugam-Burtz; Philippe Cuvillon; Marion Faucher; Camille Vaisse; Younes El Amine; Hélène Beloeil; Marc Leone; Eric Noll; Vincent Piriou; Sigismond Lasocki; Jean-Etienne Bazin; Bruno Pereira; Samir Jaber
Journal:  JAMA       Date:  2020-01-21       Impact factor: 56.272

2.  Normal Saline solutions cause endothelial dysfunction through loss of membrane integrity, ATP release, and inflammatory responses mediated by P2X7R/p38 MAPK/MK2 signaling pathways.

Authors:  Joyce Cheung-Flynn; Bret D Alvis; Kyle M Hocking; Christy M Guth; Weifeng Luo; Reid McCallister; Kalyan Chadalavada; Monica Polcz; Padmini Komalavilas; Colleen M Brophy
Journal:  PLoS One       Date:  2019-08-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.